ACR2022 - Day 3.2

Bouncebackability portends increased risk of adverse outcomes in RA Dr. Richard Conway discusses Abstract 2218 at ACR22 Convergence. Abstract 2218: Frailty Is Associated with Serious Infections in Biologic and Targeted-synthetic DMARD Treated Patients with Rheumatoid Arthritis

Deucravacitinib in PsA Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial

Efficacy and Safety Results from BE OPTIMAL in PsA Dr. Arthur Kavanaugh discusses abstract L02 ACR22 Convergence in Philadelphia, PA.  L02: Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study

Hydroxychloroquine Update from ACR22 Dr. Michelle Petri reviews several abstracts presented at ACR22 Convergence. Abstracts 0343, 0538, 0976, 0983, 0981, 0980

RA: Steroids are bad, again Dr. Richard Conway discusses Abstract 2219 at ACR22 Convergence Abstract 2219: Time-Dependent Evaluation of Glucocorticoid Exposure Duration and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis

Tapering TNFi in nonradiographic AxSpA Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.

Tofacitinib and RA-ILD Dr. Richard Conway discusses Abstract 2251 at ACR22 Convergence.  Abstract 2251: Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib

Life or Organ Threatening SLE: What To Do? Is There Anything New? Dr. Michelle Petri discusses Abstracts 1651, 1677 at ACR22 Convergence in Philiadelphia, PA.